Report contents
Industry landscape
Where the company competes: two franchises, two different clocks
Johnson & Johnson is now two businesses with little in common except a balance sheet. The company completed the separation of its consumer health arm, Kenvue, in May 2024, leaving Innovative Medicine, which sells patented prescription drugs, and MedTech, which sells devices used in surgery and interventional procedures. Both compete in global markets with high barriers. But the asset that protects the first is a patent, which expires on a known date, and the asset that protects the second is a surgeon's habit, which decays slowly if the company keeps the products competitive. That difference shapes everything about how durable the franchise is.
Innovative Medicine: the patent is both the asset and the clock
This segment sells drugs in immunology (Stelara, Tremfya), oncology (Darzalex, Carvykti), neuroscience (Spravato, Invega), pulmonary hypertension (Opsumit, Uptravi) and infectious disease. The economics are unusual. Discovery, clinical trials and biologic manufacturing are largely fixed costs, so the marginal cost of a dose is small and the gross margin on a protected product is wide. The company keeps the spread between those costs and the reimbursement price the payer agrees to.
The constraint sits downstream. In the United States, pharmacy benefit managers and insurers decide formulary position and extract rebates; in Europe, national assessment bodies set reimbursement country by country. Wholesalers distribute the product but earn thin spreads and hold little power. So the profit pool is contested between the patent holder and the payer, and the patent holder's leverage is strongest early in a product's life and gone at expiry. J&J has run that cycle before with Remicade, and Stelara's loss of US exclusivity has been the live version of it.
The competitive boundary is global for research and manufacturing, because a Phase 3 program and a fill-finish plant are fixed-cost and scale-driven, but national for price. A strong US position buys nothing in a German tender. Within that global frame, competition happens molecule by molecule inside therapeutic classes, where two or three products typically take most of a class's revenue. That makes the relevant arena narrower than "pharma": it is inflammatory bowel disease, multiple myeloma, electrophysiology-adjacent cardiology, and so on.
At the level of the whole market, structure is fragmented. Merck, Pfizer, AbbVie, Roche, Novartis, AstraZeneca and Sanofi all compete across overlapping categories, and no single company holds a dominant slice of global prescription spending. Concentration is high within a class and low across the market. Drug pricing legislation adds a structural price-setter that did not exist a few years ago: Medicare now negotiates prices for selected single-source drugs, with eligibility tied to time on market. That does not open the door to new entrants, but it shortens the period in which a successful molecule earns an unconstrained price.
MedTech: the customer is a hospital, the barrier is a trained hand
MedTech sells orthopaedics (DePuy Synthes), surgical staples and energy devices (Ethicon), contact lenses and intraocular lenses (Johnson & Johnson Vision), and interventional equipment including Biosense Webster's electrophysiology catheters and Abiomed's heart pumps. Here the buyer is a hospital or health system, often contracting through a group purchasing organization that aggregates volume across members and presses on price. The ultimate payer is an insurer or a government program.
Switching costs are real but local. A surgeon is trained on a particular instrument set; a hospital has built inventory, sterilization and scheduling around it; a cath lab has committed to a mapping system that its catheters plug into. Those frictions protect an incumbent's position in a given account, and they are why device markets tend to move slowly in both directions. They are not absolute. Rivals win business by bundling across product lines, by pricing to the contract, and by bringing clinical data for a new implant generation.
The geographic scope matches pharma: approvals are national, and so are reimbursement rules and tender cycles, while manufacturing and development carry global scale.
| Arena | What sets the price | Where bargaining power sits | Main barrier to entry |
|---|---|---|---|
| Innovative Medicine | Reimbursement decisions per country, bounded by patent life | Consolidated payers during exclusivity; biosimilar entrants after | Clinical evidence, patent estate, biologic manufacturing |
| MedTech | Hospital and GPO contracts, procedure volumes | Hospitals and GPOs, offset by surgeon preference | Device approval, surgeon training, installed base |
The structure favors scale but not permanence
Both arenas pass the concentration test in the sense that only a handful of firms can run a global development program and a regulated manufacturing network. Approval timelines, clinical evidence requirements and the cost of a commercial sales force are genuine entry barriers, and they are higher in pharma than in devices. What the structure does not provide is stability. Pharma revenue is rented from the patent clock, and the price of the rental is now partly set by Medicare. Devices face a buyer that has spent two decades consolidating its purchasing power.
That leaves the question the rest of this analysis has to answer: whether J&J's particular portfolio, spread across two franchises and many therapeutic areas, converts that scale into returns that survive the expiry dates. Diversification across molecules lowers the risk that any one cliff is fatal. It does not by itself create pricing power, and the evidence on whether the company earns returns above its cost of capital through a full patent cycle is what separates a wide moat from a well-run collection of good businesses.
Competitive advantage
Does the company have a moat? Yes, a portfolio of expiring ones
Moat: Fairly Strong. Johnson & Johnson does not own one barrier; it owns a dozen small ones, each carrying an expiration date, and the durability sits in the portfolio rather than in any single product. The clearest evidence is that cash keeps arriving when reported earnings lurch. Operating cash flow landed between $21.19 billion and $24.53 billion in every year from FY2021 to FY2025. Over the same span net income ran from $14.07 billion in FY2024 to $35.15 billion in FY2023, even though operating income barely moved between those two years, at $22.15 billion and $21.85 billion. The swings sat below the operating line; the cash engine did not.
Concentration supports that record. Only a handful of firms can run a global Phase 3 program, staff specialist sales forces across twenty countries and keep a regulated manufacturing network at inspection standard, so supply in both of J&J's arenas sits with a short list. Above-normal returns follow: an estimated after-tax return on invested capital (ROIC, operating profit after tax divided by the equity, debt and other capital tied up in the business) averaged about 19% across FY2021–FY2025. High profits alone prove nothing. Drug companies routinely earn them on one molecule and hand them back at expiry. What counts is that J&J's returns held while its largest product lost US exclusivity and the nine-month revenue base still grew.
Market position: scale is not in doubt, share is not measured
Market position: Fairly Strong. Revenue reached $94.19 billion in FY2025, up from $78.74 billion in FY2021, a 4.6% compound annual gain, and the nine months to September 30, 2026 added 7.4% to $74.77 billion. That is the profile of a company holding its ground in both arenas while one large revenue stream drains away.
Public filings do not give a like-for-like share series for either segment, so rank has to be inferred from scale. The inference is sound: a company that funds global development in drugs and devices at the same time sits in the top tier of each, and no competitor matches that combination. It stops short of proving a leading share in any single therapeutic class, where two or three molecules typically split most of a market.
Stability: Moderate. Revenue rose in each of the five fiscal years and again through the first nine months of FY2026. But growth is not share, and the treadmill is visible: the portfolio has to replace one large revenue stream every few years, and replacements cost more to develop than the originals did. Five years of measured share stability cannot be confirmed from a revenue record, which shows replacement rather than retention against rivals.
Profitability: the returns clear the bar, reported earnings do not
Returns: Fairly Strong. NOPAT is estimated as operating income taxed at an assumed 21%; invested capital is total equity plus total debt minus cash at each year-end. A flat tax rate keeps the series comparable, because the reported effective rate swung between roughly 5% and 18% over these years.
Estimated after-tax ROIC, USD bn except the final column:
| Fiscal year | Operating income | NOPAT (est.) | Invested capital | ROIC (est.) |
|---|---|---|---|---|
| FY2021 | 20.94 | 16.54 | 93.29 | 17.7% |
| FY2022 | 21.01 | 16.60 | 103.56 | 16.0% |
| FY2023 | 21.85 | 17.26 | 76.24 | 22.6% |
| FY2024 | 22.15 | 17.50 | 84.01 | 20.8% |
| FY2025 | 25.60 | 20.22 | 109.77 | 18.4% |
Two details matter. The FY2023 figure is flattered by a smaller invested-capital base, so the trend line is less smooth than the numbers suggest. And $48.77 billion of goodwill sits inside FY2025 invested capital: these returns are struck after paying for acquisitions, which is the honest way to count them and the conservative one. Against an assumed 8% cost of capital, the FY2025 spread of roughly 10 points on $109.77 billion of capital implies about $11.4 billion of annual economic profit (estimated). ROE, which ranged from 20.1% to 48.3% over the same years, is the wrong lens here: buybacks have left equity thin at $81.54 billion against $197.43 billion of assets, so leverage and accounting flatter it.
Margins: Fairly Strong. Gross margin held between 66.3% and 70.3% in FY2021–FY2025 and was 68.1% in the quarter ended September 30, 2026. Operating margin stayed in a 24.9%–27.2% band. The gross line is the pricing test, and it passed while a major patent lapsed. Net margin is the noisy one, running from 15.8% to 41.3%, because the big swings sit below operating income: FY2023 and FY2024 earned almost identical operating profit and reported wildly different bottom lines. The first nine months of FY2026 show the same pattern, with a 26.0% operating margin and a 14.7% net margin after a third quarter that turned $5.85 billion of operating income into $0.21 billion of net income.
Overall rating: Fairly Strong
Profitability is the deciding dimension and it rates Fairly Strong, so the overall call follows it. The company earns roughly double its cost of capital, on a capital base that includes the goodwill from its acquisitions, and it did so through the loss of its biggest patent. That is a real barrier at work.
It falls short of Strong because half the company rents its protection from a patent office with a fixed term, and a new price-setter now sits across the table. It clears Moderate because the returns have survived an exclusivity loss that would have broken a single-product franchise, and because cash conversion did not wobble while the earnings did.
Where the advantage comes from: trained hands in devices, patents in drugs, scale in both
Three sources carry the rating, and they decay at different speeds. The fastest test of all three is the gross margin, because it captures price and mix together and moves before revenue does.
Customer captivity: Fairly Strong in devices, Moderate in drugs
A hospital that has standardized on J&J's orthopedic implants has built inventory, sterilization trays and operating-room scheduling around them, and its surgeons have rehearsed the instrumentation. Switching means retraining and a stretch of longer procedures. A cath lab that maps with Biosense Webster's system buys catheters built to plug into it. That captivity rests on physical capital and trained habit, which is why device prices hold at contract renewal even with group purchasing organizations pressing on them. Medicine works differently. A prescriber's habit helps at the margin, but the payer sets the formulary, and once a patent lapses a discounted biosimilar takes the volume within a couple of contracting cycles. Captivity in drugs has a legal end date; in devices it has a technology end date, which is softer.
The financial signature is in the gross margin, the single metric that tests this moat fastest. The band held within about four points across FY2021–FY2025, cited earlier, which means price and mix survived the portfolio's largest patent loss. At FY2025 revenue, each percentage point of gross margin is worth roughly $0.94 billion of gross profit (estimated), so the width of that band is worth close to $3.8 billion. What breaks it: a formulary exclusion on a major drug, or a rival mapping system that converts a whole electrophysiology account. Either would show up as gross margin slipping while revenue still grows.
Scale in development and commercial reach: Moderate
Revenue grew 19.6% from FY2021 to FY2025 while operating income grew 22.3%. The incremental operating margin works out to about 30%, above the 26%–27% earned on the base, so scale is producing modest operating leverage rather than just size. The fixed costs that make this work are the trial programs, the regulatory filings and the sales forces, all of which spread across a wider base and let the company absorb a failed program without cutting elsewhere.
What tempers the rating is that distribution can be rented. A rival holding a better molecule can license it, partner, or buy a sales force, so J&J's scale shortens a competitor's launch curve without closing the door. The goodwill balance says the same thing about J&J itself: $48.77 billion at FY2025 is about 60% of book equity, so a meaningful share of growth has been purchased rather than built. What breaks the advantage: goodwill rising faster than operating income across several years would mean the company is buying revenue it cannot earn a return on.
Patents and regulation: Moderate, a barrier that expires by design
Approval requirements, quality systems and a patent estate are genuine barriers to entry, and they are higher in drugs than in devices. The same system also sets the exit. Medicare now negotiates prices for selected single-source drugs, with the first negotiated prices in effect since January 1, 2026, which does not admit entrants but compresses the profitable tail of a product's life. The barrier and the clock are the same institution. What breaks the advantage: a negotiation round or a biosimilar wave that reaches two large products in the same fiscal year, leaving the portfolio to replace more revenue at once than it has had to so far.
Durability: the leases expire on different dates
Substitutes are the live risk, and they differ by franchise. In drugs, an oral alternative that spares patients an infusion can take a class even before the patent lapses. In devices, procedures migrating to ambulatory surgery centers shift the buyer toward cost-conscious accounts, which erodes pricing without eroding the clinical need.
The portfolio structure is what makes this hold together: no single expiration can take the company down, and the device half supplies a slower-decaying base that funds the drug half's replacement cycle. Brand recognition is not part of the answer, since the consumer names went with Kenvue. The barrier is captivity plus relative scale, strongest where the captivity is physical and weakest where it is contractual. Gross margin is where erosion will surface first: a drop below roughly 65% while revenue is still rising would say the pricing power behind the rating is going, whatever the top line does.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow Johnson & Johnson compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on Johnson & Johnson
Johnson & Johnson
Business, moat and key questions
Open company page